545 related articles for article (PubMed ID: 34088832)
21. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
[TBL] [Abstract][Full Text] [Related]
22. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
23. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
24. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J; Wang S; Guo R; Liu D
Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.
Pan F; Pan R; Hu R; Zhang H; Lei S; Zhang L; Zhou C; Zeng Z; Tian X; Xie Q
J Cell Mol Med; 2024 May; 28(10):e18395. PubMed ID: 38774995
[TBL] [Abstract][Full Text] [Related]
26. CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model.
Tan IL; Arifa RDN; Rallapalli H; Kana V; Lao Z; Sanghrajka RM; Sumru Bayin N; Tanne A; Wojcinski A; Korshunov A; Bhardwaj N; Merad M; Turnbull DH; Lafaille JJ; Joyner AL
Oncogene; 2021 Jan; 40(2):396-407. PubMed ID: 33159168
[TBL] [Abstract][Full Text] [Related]
27. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
28. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
DeNardo DG; Brennan DJ; Rexhepaj E; Ruffell B; Shiao SL; Madden SF; Gallagher WM; Wadhwani N; Keil SD; Junaid SA; Rugo HS; Hwang ES; Jirström K; West BL; Coussens LM
Cancer Discov; 2011 Jun; 1(1):54-67. PubMed ID: 22039576
[TBL] [Abstract][Full Text] [Related]
29. Identification and Functional Analysis of EPOR
Li Y; Li M; Wei R; Wu J
J Immunol Res; 2020; 2020():9374240. PubMed ID: 32908942
[TBL] [Abstract][Full Text] [Related]
30. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract][Full Text] [Related]
31. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
[TBL] [Abstract][Full Text] [Related]
32. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
[TBL] [Abstract][Full Text] [Related]
33. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA; Weisser M; Jacob W; Jegg AM; Ries CH; Rüttinger D
J Immunother Cancer; 2017 Jul; 5(1):53. PubMed ID: 28716061
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
35. The CSF1-CSF1R pathway in the trigeminal ganglion mediates trigeminal neuralgia via inflammatory responses in mice.
He Z; Xu C; Guo J; Liu T; Zhang Y; Feng Y
Mol Biol Rep; 2024 Jan; 51(1):215. PubMed ID: 38281257
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
Awasthi BP; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Chem Biol Interact; 2023 Jan; 369():110255. PubMed ID: 36368339
[TBL] [Abstract][Full Text] [Related]
37. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.
Yeung J; Yaghoobi V; Miyagishima D; Vesely MD; Zhang T; Badri T; Nassar A; Han X; Sanmamed MF; Youngblood M; Peyre M; Kalamarides M; Rimm DL; Gunel M; Chen L
Neuro Oncol; 2021 Nov; 23(11):1922-1935. PubMed ID: 33914067
[TBL] [Abstract][Full Text] [Related]
38. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
[TBL] [Abstract][Full Text] [Related]
39. Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.
Maldonado MDM; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2023 Oct; 72(10):3349-3362. PubMed ID: 37505292
[TBL] [Abstract][Full Text] [Related]
40. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
